US FDA Approves Shorla Oncology’s Nelarabine Injection to Treat T-Cell Leukemia

Nelarabine Injection, an oncology drug developed by Shorla Oncology, has received US FDA approval for the treatment of T-cell Acute Lymphoblastic Leukemia (T-ALL) and T-cell Lymphoblastic Lymphoma (T-LBL). Nelarabine Injection offers patients a substitute for a product that has historically been scarce. Sharon Cunningham, CEO and co-founder of Shorla Oncology, said that they are very […]

Continue Reading

US: Lilly Drops Insulin Cost by 70%

The most popular insulins manufactured by Eli Lilly will have seen significant price reductions. Eli Lilly, a pharmaceutical company, has announced plans to reduce the price of its Humalog and Humulin insulins by 70%. This price cut was made public after the price of insulin skyrocketed, which was heavily criticized by lawmakers in the United […]

Continue Reading

US FDA Approved Alembic Pharma’s Colon Cancer Injection

The US FDA approved Alaembic Pharma’s Fluorouracil Injection USP, 2.5 g/50 mL (50 mg/mL) in India. Patients with colon and rectal adenocarcinomas, breast adenocarcinomas, gastric adenocarcinomas, and pancreatic adenocarcinomas are treated with the injection. Fluorouracil Infusion has an expected market size of $5 million for a considerable length of time finishing December 2022, as indicated […]

Continue Reading

US FDA Approves Moderna’s Skin Cancer Therapy

On, February, 22, 2023, Moderna Inc. said that US regulators have given its experimental personalised mRNA skin cancer vaccine and Merck & Co.’s drug Keytruda the designation of breakthrough therapies as an additional treatment for high-risk patients. After the market closed Moderna shares rose 2.5% to $164. Based on data from a mid-stage drug study […]

Continue Reading